Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Xbrane Biopharma AB ( (SE:XBRANE) ).
Xbrane Biopharma AB’s 2026 annual general meeting approved the company’s income statements and balance sheets and decided that no dividend will be paid, with all profits carried forward. The board and CEO were discharged from liability for 2025, signalling shareholder support for management’s handling of the past financial year.
Shareholders re-elected four directors, including chairman Anders Tullgren, and confirmed PricewaterhouseCoopers AB as auditor, while slightly adjusting board and committee remuneration. The AGM also adopted updated guidelines for executive pay and authorized the board to issue new shares, convertibles and warrants of up to 25 percent of current share capital, providing flexibility for future financing and potential strategic transactions.
More about Xbrane Biopharma AB
Xbrane Biopharma AB is a Swedish biotechnology company focused on developing and manufacturing biosimilar pharmaceuticals. Operating from Solna, it targets the global market for cost-effective biologic therapies, positioning itself within the competitive biopharma sector that serves healthcare systems seeking lower-priced alternatives to originator biologic drugs.
Average Trading Volume: 64,612
Technical Sentiment Signal: Sell
Current Market Cap: SEK203.6M
See more data about XBRANE stock on TipRanks’ Stock Analysis page.